HER2-POSITIVE GASTRIC CANCER
Clinical trials for HER2-POSITIVE GASTRIC CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE GASTRIC CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE GASTRIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: triple therapy targets HER2-positive tumors
Disease control Recruiting nowThis study tests whether adding a new experimental drug (HLX22) to standard treatment can help people with advanced HER2-positive stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 550 adults who have not had prior treatment for the…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 17, 2026 01:02 UTC
-
New drug cocktail shows promise for tough stomach cancer
Disease control Recruiting nowThis study is testing whether adding a drug called fruquintinib to standard chemotherapy and trastuzumab can help control advanced HER2-positive stomach or gastroesophageal junction cancer. It is for people who have not had prior treatment for their metastatic disease. The goal i…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase: PHASE1, PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Hope for stomach cancer: new combo aims to outperform standard care
Disease control Recruiting nowThis study tests a new drug combination (rilvegostomig plus chemotherapy and trastuzumab deruxtecan) against the current standard treatment for advanced HER2-positive stomach cancer. About 840 adults whose cancer has spread and who have not had prior treatment will participate. T…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:41 UTC